Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Trial Details

NCT ID

NCT05722405

Phase

PHASE4

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

• Ixazomib plus low-dose lenalidomide
• Ixazomib

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Patients with a confirmed diagnosis of symptomatic multiple myeloma with high-risk genetic features (1q21 amplification/t(4;14)/t(14;16)/t(14;20)/1…
• After induction and consolidation of the VRD regimen (where patients younger than 65 years of age who are eligible for autologous HSCT and are will…
• Expected survival beyond 6 months
• Age 18 to 80 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.